ClinicalTrials.gg
CompletedNCT06433661Updated Oct 10, 2025

A Research Study of the Effect of Food on Etavopivat in Healthy Participants

A Phase 1 interventional study of Etavopivat in Healthy Volunteers Sickle Cell Disease, Thalassemia, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies in Thalassemia with a site in United States — 9 open to participants now, 20 under way, 8 of them phase 3. Thalassemia · United States.

Enrollment
50th of 81
16 · median 24
Started
2024
with 2 others
Phase 1
14 of 104
1 open now
Registered
98th of 104
by date
Lead sponsor
4 of 104
Novo Nordisk A/S

Among the 104 studies in Thalassemia with a site in United States, this one is the 50th largest by enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2024, is one of 14 in phase 1, and was the 98th registered.

Thalassemia

250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.

Browse Thalassemia studies →

Open to participants now

9 of the 104 studies in Thalassemia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Thalassemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of food on the amount of etavopivat in the bloodstream of healthy participants. Participants will take a single oral dose of etavopivat following a high-fat meal (i.e. fed) and on an empty stomach (i.e fasted) on two separate occasions.The study will last up to 50 days (including screening).

03

Conditions studied

  • Healthy Volunteers Sickle Cell Disease, Thalassemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age 18-55 years (both inclusive) at the time of signing the .
  • (BMI) between 18.5 and 39.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening.
  • Body weight greater than or equal to (≥) 40.0 kilogram (kg) at screening.
  • Considered to be generally healthy based on the medical history, physical examination and the results of vital signs, (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods.
  • Participation (i.e., signed ) in any other interventional clinical study within 30 days or 5 times the half-life of the previous medicinal product (IMP) (if known), whichever is longer before screening.
  • Any disorder, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
  • Use of tobacco and nicotine products, defined as any of the below:
  • Has used any product containing tobacco or nicotine within 90 days prior to screening,
  • Unable or unwilling to refrain from the use of any product containing tobacco or nicotine throughout the study,
  • Positive nicotine test at screening.
  • Participant is unable to refrain from or anticipates the use of any drug known to be a moderate or strong inhibitor or inducer of uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, cytochrome P450 (CYP) 3A4, CYP2C9 or permeability glycoprotein (P-gp), including St. John's Wort, for 28 days prior to dosing and throughout the study.
  • Participant is unable to refrain from or anticipate the use of any medications or substances prohibited in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Sequence 1: Etavopivat: fed-fasted

    Participants will receive a single dose of Etavopivat in fed condition in period 1 and a single dose of Etavopivat in fasted condition in period 2.

    Drug: Etavopivat

  • Experimental
    Sequence 2: Etavopivat: fasted-fed

    Participants will receive a single dose of Etavopivat in fasted condition in period 1 and a single dose of Etavopivat in fed condition in period 2.

    Drug: Etavopivat

Interventions

  • Participants will receive single dose of oral Etavopivat in each treatment period.

06

What researchers measure

Primary outcomes

  1. AUC0-inf, etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose

    Measured as hours nanograms per milliliter (h\*ng/mL).

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

  2. Cmax, etavopivat: Maximum observed etavopivat plasma concentration after a single dose

    Measured as nanograms per milliliter (ng/mL).

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

Secondary outcomes

  1. AUC0-last, etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours to the time of last quantifiable concentration

    Measured as hours nanograms per milliliter (h\*ng/ml).

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

  2. tmax, etavopivat: Time to maximum observed etavopivat plasma concentration after a single dose

    Measured as hours.

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

  3. t1/2, etavopivat: Terminal half-life for etavopivat after a single dose

    Measured as hours.

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

  4. CL/Fetavopivat: Apparent plasma clearance of etavopivat after a single dose

    Measured as liter per hours (L/h).

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

  5. Vz/Fetavopivat: Apparent volume of distribution of etavopivat after a single dose based on plasma concentration values

    Measured as liters (L).

    Time frame: From 0 to 120 hours after IMP administration (V2/V6)

  6. Number of adverse events

    Measured as count of events.

    Time frame: From IMP administration on day 1 to completion of the end of study visit (V10)

07

Study locations

1 site
  • ICON-Salt Lake City
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jul 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 30, 2024
StartActual
May 28, 2024
Primary completionActual
Jul 6, 2024
CompletionActual
Jul 8, 2024
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06433661
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 30, 2024
Start date
May 28, 2024
Primary completion
Jul 6, 2024
Completion
Jul 8, 2024
Last update
Oct 10, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etavopivat

Start the discussion